Figure 3 - Efficacy, safety, usability, and acceptability of risankizumab 150 mg formulation administered by prefilled syringe or by an autoinjector for moderate to severe plaque psoriasis

Figure 3. Mean SIAQ baseline PRE module domain scores and week 16 POST module domain scores and SIAQ POST module domain scores over time with risankizumab and placebo (study 1) and OL risankizumab (study 2). Observed case analysis. AI: autoinjector; BL: baseline; OL: open-label; PFS: prefilled syringe; SIAQ: Self-Injection Assessment Questionnaire.

Mean SIAQ baseline PRE module domain scores and week 16 POST module domain scores and SIAQ POST module domain scores over time with risankizumab and placebo (study 1) and OL risankizumab (study 2). Observed case analysis. AI: autoinjector; BL: baseline; OL: open-label; PFS: prefilled syringe; SIAQ: Self-Injection Assessment Questionnaire.

Go to figure page

Reference

Efficacy, safety, usability, and acceptability of risankizumab 150 mg formulation administered by prefilled syringe or by an autoinjector for moderate to severe plaque psoriasis - Scientific Figure on ResearchGate. Available from: https://www.researchgate.net/figure/Mean-SIAQ-baseline-PRE-module-domain-scores-and-week-16-POST-module-domain-scores-and_fig2_351363564 [accessed 20 May 2025]

Caption

Figure 3. Mean SIAQ baseline PRE module domain scores and week 16 POST module domain scores and SIAQ POST module domain scores over time with risankizumab and placebo (study 1) and OL risankizumab (study 2). Observed case analysis. AI: autoinjector; BL: baseline; OL: open-label; PFS: prefilled syringe; SIAQ: Self-Injection Assessment Questionnaire.

Embed code

<a href="https://www.researchgate.net/figure/Mean-SIAQ-baseline-PRE-module-domain-scores-and-week-16-POST-module-domain-scores-and_fig2_351363564"><img src="https://www.researchgate.net/publication/351363564/figure/fig2/AS:1026823458668555@1621825198962/Mean-SIAQ-baseline-PRE-module-domain-scores-and-week-16-POST-module-domain-scores-and.png" alt="Mean SIAQ baseline PRE module domain scores and week 16 POST module domain scores and SIAQ POST module domain scores over time with risankizumab and placebo (study 1) and OL risankizumab (study 2). Observed case analysis. AI: autoinjector; BL: baseline; OL: open-label; PFS: prefilled syringe; SIAQ: Self-Injection Assessment Questionnaire."/></a>